|
|
 |
|
Viewing report
|
|
|
|
Diagnostics for the Developing World: Supporting Global Citizenship
Decision Resources, Inc, Oct 2011
Best outcomes in disease management begin with early diagnosis, which can reduce morbidity, mortality, and negative economic impact. Nowhere are differential and definitive diagnostics more important than in underserved populations for whom poor infrastructure and systemic instability are ever-present barriers to accessibility. Multitudes of opportunities exist in diagnostics development, particularly to address the detection of neglected tropical diseases (NTDs) in developing countries. Companies of all sizes are beginning to avail themselves of resources to develop minimally invasive disease analytics that are both reliable and portable far away from clinics and reference labs. A sound strategy to meeting the needs of the developing world through diagnostics is through the formation of partnerships of people, communities, governments, companies, and nonprofit funding groups. The benefits of diagnostics could accrue immediately, and rewards to companies can be both tangible and lasting.
Questions answered in this report:
- Early and accurate diagnosis can offer patients lifesaving and quality-of-life opportunities, particularly for those affected with NTDs. What characteristics of a diagnostic test are ideal for use in developing countries? Which NTDs are most in need of better diagnostic solutions? What type of a response have companies, government, and nonprofit organizations given to address these needs?
- Diagnostics in the developed world are generally created to respond to a different set of needs than those that are for the developing world. What is the greatest need in diagnostic testing in the developing world? What other factors are associated with ensuring diagnostic testing is used?
- Standard business models that shareholders typically embrace do not involve investing in products slated for low margins; yet, interest from Big Pharma and venture capital firms has increased to support product development for underserved populations. What are some examples of new models that go against the norm? How have novel partnerships supported the concept of social responsibility and global citizenship? What types of incentives continue to attract investment from nontraditional and traditional sources of funding?
Scope:
Indications featured: Tuberculosis, malaria, HIV, Chagas disease, schistosomiasis.
Innovative funding models: corporate licensing, promises to purchase, government grants, funding by nonprofit groups, for-profit shared investing.
Companies to watch: Roche Diagnostics; Abbott Laboratories; GlaxoSmithKline (GSK); Siemens Healthcare; Becton, Dickinson and Company (BD); Philips Healthcare; bioMérieux Clinical Diagnostics; MorphoSys.
|
|
|
|
